Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Diagnostic Procedure > Sentinel Lymph Node Biopsy

Sentinel Lymph Node Biopsy

Sentinel Lymph Node Biopsy is a surgical procedure used to identify and examine the first lymph node(s) to which cancer cells are likely to spread from a primary tumor.
This minimally-invasive technique allows for accurate staging of certain cancers, such as melanoma and breast cancer, while reducing the need for more extensive lymph node dissection.
Sentinel lymph node mapping involves injecting a tracer dye or radioactive substance near the tumor site to identify the sentinel node(s) for removal and pathological analysis.
This procedure can help determine the extent of disease and guide subsequent treatment decisions.

Most cited protocols related to «Sentinel Lymph Node Biopsy»

1
Optimal Lymph Flow for Breast Cancer
We recruited women who were over age 21, first time diagnosis of breast cancer (Stage I-III), and scheduled for surgical treatment, including lumpectomy or mastectomy, sentinel lymph node biopsy (SLNB) or axillary lymph node dissection ALND). Women with metastatic cancer (Stage IV), prior history of breast cancer and lymphedema, and bilateral breast cancer were excluded. Between April 2010 and June 2012, we prospectively enrolled 140 women and followed the participants for 12 months after surgery. All the participants received the The-Optimal-Lymph-Flow program.
Fu M.R., Axelrod D., Guth A.A., Cartwright F., Qiu Z., Goldberg J.D., Kim J., Scagliola J., Kleinman R, & Haber J. (2014). Proactive Approach to Lymphedema Risk Reduction: A Prospective Study. Annals of surgical oncology, 21(11), 3481-3489.
Publication 2014
Axilla Diagnosis Lumpectomy Lymph Lymphedema Lymph Node Dissection Malignant Neoplasm of Breast Mastectomy Neoplasm Metastasis Operative Surgical Procedures Sentinel Lymph Node Biopsy Woman
2
Melanoma Sentinel Lymph Node Dissection
MSLT-II, an international, multicenter, randomized, phase 3 trial to evaluate the usefulness of completion lymph-node dissection in patients with melanoma and sentinel-node metastases, consisted of a screening phase in which patients were enrolled before sentinel-node biopsy and a randomization phase in which completion lymph-node dissection was compared with observation and nodal ultrasonography (Fig. 1). The trial was conducted at 63 centers.
MSLT-II was designed by the MSLT-II executive committee with input from the pathology and ultrasonography oversight committees (see the Supplementary Appendix, available with the full text of this article at NEJM.org). Data were collected prospectively on paper and later on Web-based case-report forms. The authors vouch for the accuracy and completeness of the data and analyses reported and for the fidelity of the trial to the protocol, available at NEJM.org.
Nodal metastasis was determined by means of standard pathological assessment (including immunohistochemical tests performed according to institutional protocols) or by means of a previously described quantitative reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay during the screening phase.15 (link) Patients had to have undergone randomization and completion lymph-node dissection within 140 days after diagnostic biopsy.
The randomization phase involved enrollment of patients who had undergone screening and had pathologically or molecularly positive sentinel-node metastases and patients who had not undergone screening in whom sentinel-node metastases were detected by means of pathological assessment. In the randomization phase, fewer patients with RT-PCR–positive findings than anticipated were enrolled. In 2012, the data and safety monitoring board determined that such patients should no longer undergo randomization, since attainment of sufficient power to evaluate a therapeutic effect in that group was not feasible. The data and safety monitoring board recommended continued follow-up of these patients to assess outcomes.
At the third interim analysis, the data and safety monitoring board determined that detection of a significant survival difference between the trial groups was unlikely and recommended that the current primary end-point data be released. Intention-to-treat and per-protocol analyses of the outcome variables showed similar results. Results of per-protocol analyses are reported in this article, since they are likely to be the most clinically pertinent. The intention-to-treat data for the primary end point (melanoma-specific survival) are provided in Figure S1 in the Supplementary Appendix.
Faries M.B., Thompson J.F., Cochran A.J., Andtbacka R.H., Mozzillo N., Zager J.S., Jahkola T., Bowles T.L., Testori A., Beitsch P.D., Hoekstra H.J., Moncrieff M., Ingvar C., Wouters M.W., Sabel M.S., Levine E.A., Agnese D., Henderson M., Dummer R., Rossi C.R., Neves R.I., Trocha S.D., Wright F., Byrd D.R., Matter M., Hsueh E., MacKenzie-Ross A., Johnson D.B., Terheyden P., Berger A.C., Huston T.L., Wayne J.D., Smithers B.M., Neuman H.B., Schneebaum S., Gershenwald J.E., Ariyan C.E., Desai D.C., Jacobs L., McMasters K.M., Gesierich A., Hersey P., Bines S.D., Kane J.M., Barth R.J., McKinnon G., Farma J.M., Schultz E., Vidal-Sicart S., Hoefer R.A., Lewis J.M., Scheri R., Kelley M.C., Nieweg O.E., Noyes R.D., Hoon D.S., Wang H.J., Elashoff D.A, & Elashoff R.M. (2017). Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. The New England journal of medicine, 376(23), 2211-2222.
Publication 2017
Biological Assay Biopsy Clinical Trials Data Monitoring Committees Diagnosis Immunohistochemistry Lymph Node Dissection Melanoma Neoplasm Metastasis Patients Reverse Transcriptase Polymerase Chain Reaction Sentinel Lymph Node Sentinel Lymph Node Biopsy Therapeutic Effect Ultrasonography
3
Adjuvant Chemoendocrine Therapy Trial
We enrolled women who were at least 18 years of age and who had hormone-receptor–positive,11 (link) HER2-negative,12 (link) nodal stage N1, noninflammatory breast cancer without distant metastasis.13 (link) The participants had to have undergone primary surgery with sentinel-node biopsy or axillary lymph-node dissection and had to be eligible for a chemotherapy regimen that contained a taxane, an anthracycline, or both.
Premenopausal status was defined as less than 6 months since the last menstrual period, and postmenopausal status was defined as previous bilateral oophorectomy or more than 12 months since the last menstrual period and no previous hysterectomy. If these definitions did not apply, participants were categorized as premenopausal if they were younger than 50 years of age and as postmenopausal if they were 50 years of age or older. Full entry criteria and approved options for chemotherapy and endocrine therapy are listed in the protocol.
A representative block or unstained sections of the primary invasive tumor were sent directly to Genomic Health for testing according to standard commercial processing. Women with a recurrence score higher than 25 were ineligible for the trial, and it was recommended that they receive adjuvant chemoendocrine therapy. Women with a recurrence score of 0 to 25 were invited to participate in the trial. Participants who provided consent were randomly assigned in a 1:1 ratio to receive chemoendocrine therapy or endocrine therapy only. The stratification factors included the recurrence score (0 to 13 or 14 to 25), premenopausal or postmenopausal status, and type of axillary surgery (sentinel-node biopsy or axillary lymph-node dissection). Each participant was to be followed for 15 years after randomization.
Kalinsky K., Barlow W.E., Gralow J.R., Meric-Bernstam F., Albain K.S., Hayes D.F., Lin N.U., Perez E.A., Goldstein L.J., Chia S.K., Dhesy-Thind S., Rastogi P., Alba E., Delaloge S., Martin M., Kelly C.M., Ruiz-Borrego M., Gil-Gil M., Arce-Salinas C.H., Brain E.G., Lee E.S., Pierga J.Y., Bermejo B., Ramos-Vazquez M., Jung K.H., Ferrero J.M., Schott A.F., Shak S., Sharma P., Lew D.L., Miao J., Tripathy D., Pusztai L, & Hortobagyi G.N. (2021). 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. The New England journal of medicine, 385(25), 2336-2347.
Publication 2021
Anthracyclines Axilla ERBB2 protein, human Female Castrations Genome Hormones Hysterectomy Lymph Node Dissection Malignant Neoplasm of Breast Menstruation Neoplasm Metastasis Neoplasms Operative Surgical Procedures Pharmaceutical Adjuvants Pharmacotherapy Recurrence Sentinel Lymph Node Biopsy System, Endocrine taxane Therapeutics Treatment Protocols Woman Youth
4
Standardized Melanocytic Lesion Assessment and Treatment Guide
We gathered assessment and recommendations on each case using a standardized online histology form and then classified the diverse terms using the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) histology form.13 (link) This tool organizes pathologists’ diverse descriptive terms of melanocytic skin lesions into five diagnostic classes, with suggested treatment recommendations (table 1). Example diagnostic terms for each class (and suggested treatment recommendations, all provided under the assumption that specimen margins are positive) include: class I, nevus or mild atypia (no further treatment margin required); class II, moderate atypia (consider narrow but complete repeat excision margin <5 mm); class III, severe atypia or melanoma in situ (repeat excision with ≥5 mm but <1 cm margins); class IV, pT1a invasive melanoma (wide excision ≥1 cm margin); and class V, ≥pT1b invasive melanoma (wide excision ≥1 cm with possible additional treatment, such as sentinel lymph node biopsy and adjuvant therapy).
Elmore J.G., Barnhill R.L., Elder D.E., Longton G.M., Pepe M.S., Reisch L.M., Carney P.A., Titus L.J., Nelson H.D., Onega T., Tosteson A.N., Weinstock M.A., Knezevich S.R, & Piepkorn M.W. (2017). Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. The BMJ, 357, j2813.
Publication 2017
Diagnosis Melanocyte Melanocytic Nevus Melanoma Pathologists Pharmaceutical Adjuvants Sentinel Lymph Node Biopsy Skin Surgical Margins Therapeutics
5
Breast Cancer Bone Marrow Analysis
This study included patients (median age, 58 years) diagnosed with primary breast cancer in the South Swedish Health Care Region between June 1999 and May 2003 as well as patients diagnosed in Lund, Landskrona and Helsingborg. The patients underwent bone marrow aspiration from the sternal crest under anaesthesia at the time of primary surgery. The study was approved by the ethics committee at Lund University, and written informed consent was obtained from all included patients (LU699-09, LU75-02).
Patient and tumour characteristics are given in Table
1. Patients underwent either mastectomy or breast-conserving therapy based on preoperatively identified characteristics and staging. A sentinel node biopsy was performed in patients with no sign of axillary node engagement before surgery, followed by axillary lymph node dissection (level I and II) at the time of either the primary operation or a second operation if histopathological analysis showed metastatic involvement in the sentinel node biopsy. If node involvement was known preoperatively, axillary lymph node dissection was performed at the time of the primary surgery.
Adjuvant therapy was recommended according to clinical standards following Regional Guidelines, and included chemotherapy for N+ premenopausal women and N+ postmenopausal women with oestrogen receptor-negative tumours (ER-) (n = 65, 16%). Endocrine therapy was delivered to 197 patients (49%); premenopausal patients with oestrogen receptor-positive (ER+) tumours and no nodal engagement received tamoxifen, and postmenopausal women with ER + tumours received tamoxifen or aromatase inhibitors regardless of nodal status. Chemoendocrine therapy was given to 22 patients; 137 patients had no adjuvant therapy. Radiotherapy to the breast was given after breast-conserving surgery (50 Gy) (n = 198, 49%) and locoregional radiotherapy was delivered if four or more axillary lymph nodes were metastatic (n = 35, 9%). A combination of radiotherapy to the breast and to the locoregional lymph nodes was delivered in 39 patients (10%).
The patients were followed by annual clinical examination and mammography. Further clinical and radiological examinations were performed when clinical signs indicated recurrence of the disease. After 5 years of follow-up, all clinical and histopathological results concerning tumour grading and staging, as well as reports of events, were abstracted from individual patient’s charts. The median follow-up for patients without any breast cancer-related event was 61 months. For patients for whom no cause of death was registered, we received information from the Swedish Register of Causes of Death (Central Statistics Office). The inclusion criteria were re-evaluated.
The original cohort included 569 patients, 544 of whom were followed according to the schedule. The exclusion criteria were no standardised surgical treatment (laser, n = 1), neoadjuvant treatment (n = 11), and local recurrence (n = 3) and the sample volume was inadequate in 36 patients. The analysis was not performed in 117 patients due to change in research strategy at our laboratory. The final cohort thus included 401 patients.
Falck A.K., Bendahl P.O., Ingvar C., Isola J., Jönsson P.E., Lindblom P., Lövgren K., Rennstam K., Fernö M, & Rydén L. (2012). Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study. BMC Cancer, 12, 403.
Full text: Click here
Publication 2012
Anesthesia Aromatase Inhibitors Axilla Bone Marrow Breast Breast-Conserving Surgery Crista Ampullaris Estrogen Receptors Ethics Committees Lymph Node Excision Malignant Neoplasm of Breast Mammography Mastectomy Neoadjuvant Therapy Neoplasms Nodes, Lymph Operative Surgical Procedures Patients Pharmaceutical Adjuvants Pharmacotherapy Physical Examination Radiotherapy Recurrence Sentinel Lymph Node Biopsy Sternum System, Endocrine Tamoxifen Therapeutics Woman X-Rays, Diagnostic

Most recents protocols related to «Sentinel Lymph Node Biopsy»

1
Neoadjuvant Therapy Pathological Response
The primary endpoint was the percentage of pathological complete remissions (pCRs), which was assessed locally at the time of surgery and defined as the absence of invasive tumor cells in the breast and axilla (pCR; ypT0/Tis, ypN0). Patients underwent breast-conserving or ablative surgery, and treatment of axillary lymph nodes included sentinel lymph node biopsy or axillary lymph node dissection.
Chen H., Maimaitiaili A., Liu Z., Ling R., Zhao Y., Yang H., Liu Y., Liu K., Zhang J., Mao D., Yu Z., Liu Y., Fu P., Wang J., Jiang H., Zhao Z., Tian X., Cao Z., Wu K., Song A., Jin F., He J., Fan Z, & Zhang H. (2023). Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012). Therapeutic Advances in Medical Oncology, 15, 17588359231156146.
Publication 2023
Axilla Breast Cells Lymph Node Dissection Neoplasms Nodes, Lymph Operative Surgical Procedures Patients Sentinel Lymph Node Biopsy
2
Breast Cancer Reconstruction Outcomes
This study involved a retrospective chart review of a prospectively maintained database and was approved by the respective Institutional Review Board (IRB No. 3-2022-0162). We identified patients diagnosed with primary breast cancer, who had undergone mastectomy with DTI breast reconstruction at our hospital between August 2011 and June 2021. The exclusion criteria were previous breast surgery, refusal to sign the consent form, previous radiotherapy, follow-up period < 6 months, and missing data for the pertinent variables.
Each breast was considered individually and categorized according to the type of implant surface as textured anatomical implant or smooth round implant. The implant brands used were Mentor MemoryGel (Mentor Worldwide LLC, Irvine, USA), Allegan (Allergan plc, Dublin, Ireland), and BellaGel (Hans Biomed Corp., Seoul, Korea). Patient demographics, operative characteristics, radiation therapy, medical oncology treatments, and relevant data for the analysis of risk factors were collected by reviewing the medical records. The parameters included age, body mass index (BMI), pathologic tumor stage, mastectomy type (nipple-sparing, skin-sparing, or total mastectomy), axillary surgery (sentinel lymph node biopsy or axillary lymph node dissection), implant size, implant insertion plane, ADM use, laterality, number of dissected lymph nodes or positive lymph nodes, chemotherapy (neoadjuvant or adjuvant), target therapy (trastuzumab), hormone therapy, radiotherapy, comorbidities (diabetes mellitus or hypertension), smoking (non-smoker, ex-smoker, or active smoker), follow-up duration, and drainage duration. Furthermore, complications including capsular contracture, infection, seroma, hematoma, implant rupture, implant exposure, rippling, implant malposition, and nipple-areolar complex (NAC) necrosis were analyzed. Capsular contracture was evaluated by reconstruction surgeons. Any incidence of clinically relevant capsular contracture, defined as Spear–Baker grade III or IV, occurring during the study period was recorded.
Variables were compared between the groups using Pearson χ2 test or Fisher exact test to examine the associations of the categorical variables. The independent t-test or Mann-Whitney U test was used for continuous variables. Logistic regression models were used to evaluate the risk factors associated with the development of complications and capsular contracture. Multiple logistic regression analyses were performed using a stepwise model selection method to predict the risk factors for overall complications and capsular contracture based on the age, BMI, pathologic tumor stage, mastectomy type, axillary surgery, implant-based breast reconstruction (size, surface, and insertion plane), number of positive lymph nodes, number of dissected lymph nodes, neoadjuvant and adjuvant chemotherapy, target treatment, hormone therapy, radiotherapy, comorbidities of diabetes mellitus or hypertension, smoking, drainage duration, and follow-up duration. Further subgroup analyses were conducted to determine whether the impact of the implant surface on the risk of capsular contracture varies with higher BMI or adjuvant radiotherapy after adjusting for risk factors. We divided the patients into the following two BMI categories according to the World Health Organization classification: < 25 kg/m2 and ≥ 25 kg/m2. Statistical significance was set at p-value < 0.05. All statistical analyses were conducted using Statistical Product and Service Solutions (version 24.0; SPSS Inc., Chicago, USA).
Jeon H.B., Lee M., Roh T.S., Jeong J., Ahn S.G., Bae S.J., Lee N, & Kim Y.S. (2023). Complications Including Capsular Contracture in Direct-to-Implant Breast Reconstruction With Textured Anatomical Versus Smooth Round Implants: A Single Center Retrospective Analysis. Journal of Breast Cancer, 26(1), 25-34.
Publication 2023
Areola Axilla Breast Capsule Chemotherapy, Adjuvant Contracture Diabetes Mellitus Drainage Ex-Smokers Functional Laterality Hematoma High Blood Pressures Hormones Index, Body Mass Infection Kidney Papillary Necrosis Lymph Node Dissection Malignant Neoplasm of Breast Mammaplasty Mastectomy Mentors Neoadjuvant Therapy Neoplasms Nipples Nodes, Lymph Non-Smokers Operative Surgical Procedures Patients Pharmaceutical Adjuvants Pharmacotherapy Radiotherapy Radiotherapy, Adjuvant Reconstructive Surgical Procedures Sentinel Lymph Node Biopsy Seroma Simple Mastectomy Skin Surgeons Therapeutics Thoracic Surgical Procedures Trastuzumab
3
Minimally Invasive Lymphadenectomy Comparison
We conducted a multicenter retrospective comparative study, collecting data from January 2014 to November 2018 (Clinical Trial ID: NCT04246580; updated on 31 January 2023). All the consecutive patients with apparent early-stage EC and CC, without suspicious radiologic appearance of lymph nodal metastasis, who underwent laparoscopic or robotic systematic bilateral pelvic lymphadenectomy were included. The minimally invasive approach was chosen also in case of CC, since until November 2018 we had no strong evidence showing poorer survival outcomes with this type of surgery compared to the open surgical approach [21 (link)]. Indeed, until 2018, the laparoscopic approach was a potential alternative to laparotomic surgery because it was associated with a lower morbidity rate and similar oncologic outcomes [22 (link),23 (link),24 (link)]. Nevertheless, since 2018, much has changed in the surgical concepts of cervical and uterine cancer, including indications of minimally invasive surgery, sentinel node biopsy, and pelvic lymph node dissection, as further discussed in next sections.
Pre-operative work-up included medical history collection, physical and vaginal-pelvic examination, chest X-ray, ultrasound scans and pelvic magnetic resonance imagining (MRI) in all patients and positron emission tomography/computed tomography (PET/CT) scans in CC patients, following an algorithm previously described [25 (link)]. Patients who underwent incomplete pelvic lymphadenectomy (SLN biopsy, lymph nodes sampling) were excluded from the current analysis. All the surgical reports were analyzed to select patients who underwent ICG-guided systematic pelvic lymphadenectomy (ICG-LND) and patients who underwent standard systematic pelvic lymphadenectomy (conventional-LND). The choice to perform ICG-LND or conventional-LND was not influenced by any clinical parameter and was based on surgeon’s preference. All the histological reports were analyzed and data about the number of lymph nodes removed during surgery (primary outcome) were recorded. Furthermore, data about the type of tumor (EC or CC) and FIGO stage were collected.
The study was approved by the Institutional Review Boards of the referral center (“Regina Elena” National Cancer Institute of Rome—#CE RS1285/19(2297)) and of the participating centers. The design, analysis, interpretation of data, drafting, and revisions are in compliance with the Helsinki Declaration, the Committee on Publication Ethics guidelines, and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement [26 (link)], validated by the Enhancing the Quality and Transparency of Health Research (EQUATOR) Network. The study was not advertised, and no remuneration was offered to encourage patients to give consent for collection and analysis of their data. Each patient enrolled in this study was informed about the aims and procedures and provided their informed consent to allow data collection for research purposes.
Chiofalo B., Laganà A.S., Ghezzi F., Certelli C., Casarin J., Bruno V., Sperduti I., Chiantera V., Peitsidis P, & Vizza E. (2023). Beyond Sentinel Lymph Node: Outcomes of Indocyanine Green-Guided Pelvic Lymphadenectomy in Endometrial and Cervical Cancer. International Journal of Environmental Research and Public Health, 20(4), 3476.
Full text: Click here
Publication 2023
Biopsy Ethics Committees Ethics Committees, Research Laparoscopy Laparotomy Lymph Node Excision Lymph Node Metastasis Magnetic Resonance Imaging Medical History Taking Minimally Invasive Surgical Procedures Neck Neoplasms Nodes, Lymph Operative Surgical Procedures Patients Pelvic Examination Pelvis Physical Examination Radiography, Thoracic Radionuclide Imaging Scan, CT PET Sentinel Lymph Node Biopsy Surgeons Ultrasonography Uterine Cancer Vagina Vaginal Examination
4
Surgical Outcomes in Cervical Cancer
The Canadian Cervical Cancer Collaborative represents a database of 11 tertiary institutions across Canada, capturing all cases of surgically treated cervical carcinoma from January 2007 to December 2017. All participating sites had approval from their local Research Ethics Boards.
Inclusion criteria were age > 18 years old, squamous, adenocarcinoma, or adenosquamous histology cervical carcinoma, and primary surgical treatment. Surgical approach included both simple and radical hysterectomies performed by laparotomy, laparoscopic or robotic, or laparoscopically assisted vaginal or vaginal hysterectomy. Only patients with nodal evaluation (sentinel lymph node biopsy or lymphadenectomy) were included in the present study. For this study, all patients had to have no residual carcinoma on final hysterectomy specimen. Indication for excisional procedure was not collected, but all cases had a diagnosis of cervical carcinoma prior to definitive surgical treatment. Cases were excluded if they underwent neoadjuvant radiation therapy or chemotherapy, were stage IA1 without LVSI, stage IV, underwent trachelectomy or conization as their definitive surgery, tumors > 4 cm (by clinical exam or imaging- pre-conization), “other” histologies, or with missing pertinent information (tumor size, surgical type, final stage).
Staging was based on the pathological FIGO 2018 staging system. Recurrences were determined on the basis of either radiographic evidence or biopsy-proven recurrence. Follow up was in accordance with local standard of care. Data were collected locally at each institution and entered into a central REDCap database. Data collected included demographics (age, smoking status, ASA score, height, weight and BMI calculation), preoperative imaging (MRI and/or PET scan), operative factors (mode of surgery, lymph node assessment, uterine manipulator, complication), postoperative factors (length of stay, readmission), pathologic characteristics (FIGO 2018 pathologic staging, histology, tumor diameter, stromal invasion, lymphovascular space invasion, lymph node status, and adjuvant treatment (chemotherapy and radiotherapy), along with recurrence and follow up data.
Descriptive statistics were used to summarize demographic, treatment, and disease variables, as well as outcomes. Chi-square, Wilcoxon rank sum, and log-rank tests were used to explore for differences in characteristics based on surgical technique, as well as the potential effect of surgery on outcomes of interest. Recurrence free survival (RFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Given the small number of disease-specific events, no regression analysis was performed. All analyses and confidence intervals were two-sided and statistical significance was defined at the α = 0.05 level. SAS version 9 statistical software package was used for analysis.
Aubrey C., Pond G.R., Helpman L., Vicus D., Elit L., Plante M., Lau S., Kwon J.S., Altman A.D., Willows K., Feigenberg T., Sabourin J., Samouelian V., Bernard L., Cockburn N., Saunders N.B., Piedimonte S., Teo-Fortin L.A., Kim S.R., Sadeq N., Jang J.H., Shamiya S, & Nelson G. (2023). Oncologic Outcomes of Surgically Treated Cervical Cancer with No Residual Disease on Hysterectomy Specimen: A 4C (Canadian Cervical Cancer Collaborative) Working Group Study. Current Oncology, 30(2), 1977-1985.
Full text: Click here
Publication 2023
Adenocarcinoma Adenosquamous Carcinoma Biopsy Cervical Cancer Cervicectomy Conization Diagnosis Hysterectomy Laparoscopy Laparotomy Lymph Node Excision Neck Neoadjuvant Radiotherapy Neoplasms Nodes, Lymph Operative Surgical Procedures Patients Pharmaceutical Adjuvants Pharmacotherapy Positron-Emission Tomography Radiotherapy Recurrence Residual Cancer Sentinel Lymph Node Biopsy Uterus Vagina Vaginal Hysterectomy X-Rays, Diagnostic
5
Radical Hysterectomy and Lymph Node Assessment
All patients underwent radical hysterectomy and bilateral pelvic lymphadenectomy with or without sentinel lymph node biopsy and salpingo-oophorectomy. Pre-operative staging was performed with a pelvic ultrasound scan, abdominal MRI-scan, and chest X-ray. The surgical approach was either laparotomy or minimally invasive (laparoscopy or robotic). The radicality of hysterectomy was classified according to the Querleu–Morrow classification [16 (link)]. In the case of suspicious initial parametrial involvement in the US-scan or MRI-scan, the patient was counseled for exclusive chemo-radiotherapy to be the first choice of treatment (as per ESGO guidelines [8 (link)]) or primary radical surgery, accepting the risk of potential adjuvant chemoradiation. A dedicated gynecologic oncology pathologist analyzed the surgical specimens. Adjuvant treatment was administered in line with international guidelines according to pathologic risk factors [8 (link)].
Bizzarri N., Biscione A., Moro F., Pedone Anchora L., Catinella V., Certelli C., Teodorico E., Fagotti A., Fanfani F., Kucukmetin A., Querleu D., Ferrandina G., Scambia G, & Testa A.C. (2023). Prognostic Significance of Ultrasound Characteristics and Body Mass Index in Patients with Apparent Early-Stage Cervical Cancer: A Single-Center, Retrospective, Cohort Study. Diagnostics, 13(4), 583.
Full text: Click here
Publication 2023
Abdomen Chemoradiotherapy, Adjuvant Hysterectomy Laparoscopy Laparotomy Lymph Node Excision MRI Scans Neoplasms Operative Surgical Procedures Parametrium Pathologists Patients Pelvis Pharmaceutical Adjuvants Radiography, Thoracic Radionuclide Imaging Radiotherapy Salpingo-oophorectomy Selection for Treatment Sentinel Lymph Node Biopsy Ultrasonography

Top products related to «Sentinel Lymph Node Biopsy»

1
Intrabeam by Zeiss
Sourced in Germany
The Intrabeam is a compact, single-use radiation therapy device designed for the treatment of certain types of cancer. It delivers targeted, low-energy radiation directly to the tumor site during surgery, providing a precise and efficient treatment option. The Intrabeam's core function is to deliver localized radiation therapy to the affected area, helping to minimize damage to surrounding healthy tissue.
2
Stata 12 by StataCorp
Sourced in United States, United Kingdom, Denmark, Belgium, Spain, Canada, Austria
Stata 12.0 is a comprehensive statistical software package designed for data analysis, management, and visualization. It provides a wide range of statistical tools and techniques to assist researchers, analysts, and professionals in various fields. Stata 12.0 offers capabilities for tasks such as data manipulation, regression analysis, time-series analysis, and more. The software is available for multiple operating systems.
3
Intron a by Merck Group
Sourced in United States
Intron A is a laboratory product manufactured by Merck Group. It is a recombinant form of human interferon alpha-2b, which is a naturally occurring protein involved in the body's immune response. Intron A is used as a research tool in molecular biology and biochemistry experiments, where it can be utilized to study the role of interferon alpha-2b in various cellular processes.
4
Pinnacle planning system by Philips
Sourced in United States
The Pinnacle planning system is a medical imaging software solution developed by Philips. It is designed to assist healthcare professionals in the planning and management of radiation therapy treatments. The system provides tools for importing, visualizing, and analyzing patient data from various imaging modalities, enabling healthcare providers to develop customized treatment plans.
5
Spss statistics for windows version 21 by IBM
Sourced in United States, United Kingdom, Belgium, Japan
SPSS Statistics for Windows, Version 21.0 is a statistical software package designed for data analysis. It provides a comprehensive set of tools for data manipulation, analysis, and visualization. The software is designed to work on the Windows operating system.
6
Spss ver 24 by IBM
Sourced in United States, Japan
SPSS version 24.0 is a software application used for statistical analysis. It provides tools for data management, visualization, and predictive modeling. The software is designed to handle a wide range of data types and offers a variety of statistical techniques to analyze and interpret data.
7
Vicryl by Johnson & Johnson
Sourced in United States, Germany, Brazil, France, Australia, Italy
Vicryl is a sterile, absorbable surgical suture material composed of a copolymer of glycolic acid and lactic acid. It is designed for use in general soft tissue approximation and/or ligation, including use in ophthalmic procedures.
8
Prism 9 by GraphPad
Sourced in United States, Austria, Germany, Poland, United Kingdom, Canada, Japan, Belgium, China, Lao People's Democratic Republic, France
Prism 9 is a powerful data analysis and graphing software developed by GraphPad. It provides a suite of tools for organizing, analyzing, and visualizing scientific data. Prism 9 offers a range of analysis methods, including curve fitting, statistical tests, and data transformation, to help researchers and scientists interpret their data effectively.
9
Ligasure by Medtronic
Sourced in United States, Ireland, Japan
The LigaSure is a surgical instrument manufactured by Medtronic. It is designed to seal blood vessels, tissue bundles, and lymphatics during surgical procedures by delivering a precise combination of pressure and energy. The LigaSure device provides controlled and consistent vessel sealing, enabling efficient tissue dissection and hemostasis.

More about "Sentinel Lymph Node Biopsy"

Sentinel lymph node (SLN) biopsy is a minimally-invasive surgical technique used to identify and examine the first lymph node(s) that cancer cells are likely to spread to from a primary tumor.
This procedure is commonly used in the staging and treatment planning for certain cancers, such as melanoma and breast cancer.
SLN mapping involves injecting a tracer dye or radioactive substance near the tumor site to help locate the sentinel node(s) for removal and pathological analysis.
By identifying the sentinel node(s), this procedure can provide accurate information about the extent of disease, allowing for more targeted treatment decisions.
SLN biopsy can help reduce the need for more extensive lymph node dissection, which can have significant side effects.
The technique has been further improved with the use of advanced imaging technologies, such as Intrabeam and Pinnacle planning system, as well as statistical analysis tools like Stata 12.0, SPSS Statistics for Windows (Version 21.0 and ver. 24.0), and Prism 9.
Additionaly, the use of sutures like Vicryl and surgical sealants like LigaSure have enhanced the precision and safety of SLN biopsy procedures.
Overall, this minimally-invasive approach has become an important tool in the management of certain cancers, allowing for more accurate staging and informed treatment planning.
Reserchers are continually exploring ways to further optimize SLN biopsy protocols, such as through the use of Intron A, to improve reproducibility and accuracy.